Semaglutide is effective in type 2 diabetes and obesity with schizophrenia

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay et al. · The Lancet Diabetes & Endocrinology · 2018 · 764 citations

Medicine, Pharmacology, Pharmacotherapy +13

Semaglutide lowers body weight in rodents via distributed neural pathways

Sanaz Gabery, Casper G. Salinas, Sarah Juel Paulsen et al. · JCI Insight · 2020 · 677 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder

Julie Rask Larsen, Louise Vedtofte, Mathilde S. L. Jakobsen et al. · JAMA Psychiatry · 2017 · 227 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto et al. · The Lancet Diabetes & Endocrinology · 2020 · 203 citations

Medicine, Pharmacology, Pharmacotherapy +15

Effect of <scp>GLP</scp> ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: <scp>a</scp> randomized, placebo‐controlled trial

Pelle L. Ishøy, Filip K. Knop, Brian V. Broberg et al. · Diabetes Obesity and Metabolism · 2016 · 90 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17